Cadrenal Therapeutics, Inc. Common Stock (CVKD) Stock

Cadrenal Therapeutics, Inc. Common Stock (CVKD) is a Healthcare stock trading at $1.57 (as of 2026-08-21), with a market capitalization of $5.60M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Valuation — source: SEC EDGAR (first-party)
Price$1.57
Market Cap$5.60M
Price / Book1.37
FCF Yield-96.1%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($365524.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOQuang X. Pham
Employees4
CountryUS
IPO Date2023-01-20

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Xenetic Biosciences, Inc. (XBIO)
  • Apimeds Pharmaceuticals US, Inc (APUS)
  • Bolt Biotherapeutics, Inc. (BOLT)
  • Acurx Pharmaceuticals, Inc. (ACXP)
  • Enveric Biosciences, Inc. (ENVB)
  • Processa Pharmaceuticals, Inc. (PCSA)
  • PMGC Holdings Inc. (ELAB)
  • AEON Biopharma, Inc. (AEON)
CVKD earnings history · CVKD institutional & insider holders · CVKD KPIs & operating metrics · CVKD financials · CVKD investor presentations & press releases · CVKD SEC filings · CVKD peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.